EXACT Sciences Co. (EXAS) Director Sells $325,440.00 in Stock

EXACT Sciences Co. (NASDAQ:EXAS) Director Katherine S. Zanotti sold 7,232 shares of the firm’s stock in a transaction dated Thursday, April 12th. The shares were sold at an average price of $45.00, for a total transaction of $325,440.00. Following the completion of the sale, the director now owns 105,814 shares in the company, valued at $4,761,630. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

EXAS opened at $44.96 on Monday. EXACT Sciences Co. has a 12-month low of $23.30 and a 12-month high of $63.60. The company has a quick ratio of 6.77, a current ratio of 7.15 and a debt-to-equity ratio of 0.01. The company has a market cap of $5,519.77, a price-to-earnings ratio of -45.41 and a beta of 0.87.

How to Become a New Pot Stock Millionaire

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Thursday, February 22nd. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09. EXACT Sciences had a negative net margin of 43.01% and a negative return on equity of 24.13%. The company had revenue of $87.41 million during the quarter, compared to analyst estimates of $87.42 million. During the same period last year, the firm posted ($0.34) EPS. EXACT Sciences’s revenue for the quarter was up 148.0% compared to the same quarter last year. analysts expect that EXACT Sciences Co. will post -0.92 EPS for the current year.



A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its position in EXACT Sciences by 1.7% during the 4th quarter. BlackRock Inc. now owns 7,658,145 shares of the medical research company’s stock worth $402,358,000 after buying an additional 126,513 shares during the last quarter. Carillon Tower Advisers Inc. purchased a new position in EXACT Sciences during the 4th quarter worth approximately $66,280,000. Victory Capital Management Inc. raised its position in EXACT Sciences by 82.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,189,560 shares of the medical research company’s stock worth $62,499,000 after buying an additional 539,160 shares during the last quarter. Geode Capital Management LLC raised its position in EXACT Sciences by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 1,098,640 shares of the medical research company’s stock worth $57,722,000 after buying an additional 24,614 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its position in EXACT Sciences by 5.8% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 765,522 shares of the medical research company’s stock worth $40,221,000 after buying an additional 41,784 shares during the last quarter. 82.02% of the stock is owned by institutional investors.

A number of research firms have recently weighed in on EXAS. Bank of America set a $67.00 price target on shares of EXACT Sciences and gave the company a “buy” rating in a report on Monday, January 8th. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Zacks Investment Research raised shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a research report on Tuesday, January 16th. William Blair reaffirmed a “buy” rating on shares of EXACT Sciences in a research report on Tuesday, January 2nd. Finally, Goldman Sachs began coverage on shares of EXACT Sciences in a research report on Monday, January 29th. They issued a “neutral” rating and a $51.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $52.84.

COPYRIGHT VIOLATION WARNING: “EXACT Sciences Co. (EXAS) Director Sells $325,440.00 in Stock” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2018/04/16/exact-sciences-co-exas-director-sells-325440-00-in-stock.html.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply